As suggested in the report of Toita et al. (2016), the efficient delivery of therapeutic anti-inflammatory molecules, interleukin (IL)-10, to macrophages can dramatically improve the therapeutic efficacy of obesity treatments [18]. The gene discussed is IL10; the disease is obesity disorder.